Cariprazine hydrochloride - Chengdu Kanghong Pharmaceutical
Alternative Names: KH-734Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Chengdu Kanghong Pharmaceutical
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Mood stabilisers; Piperazines; Small molecules; Urea compounds
- Mechanism of Action 5-HT2C serotonin receptor modulators; Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Schizophrenia
Most Recent Events
- 19 Sep 2024 Preclinical trials in Schizophrenia in China (PO)
- 19 Sep 2024 Chengdu Kanghong Pharmaceutical plans a phase III trial for Acute Schizophrenia (In adults) (PO, Capusle), in October 2024 (NCT06589817)